Galera Therapeutics, INC 8-K filings

Galera Therapeutics, Inc. has completed its merger with Obsidian Therapeutics, Inc., becoming a wholly owned subsidiary and ceasing its OTCQB listing.

Galera Therapeutics, Inc. announced a one-for-two hundred reverse stock split effective July 12, 2026, to adjust its common stock.

Galera Therapeutics, Inc. has announced a one-for-two hundred reverse stock split of its common stock, effective July 12, 2026.

Galera Therapeutics announced the mandatory conversion of all outstanding Series B Preferred Stock into common stock, eliminating preferred shares and settling fractional interests with cash.

Galera Therapeutics, Inc. has amended its Certificate of Incorporation to increase authorized shares and grant stockholders the right to act by written consent, alongside adopting new Amended and Restated Bylaws.

Galera Therapeutics stockholders approved director elections, ratified auditor appointment, and authorized significant amendments to the company's charter, including a potential reverse stock split.

Galera Therapeutics and Obsidian Therapeutics announce a definitive merger agreement, creating a combined entity focused on advancing Obsidian's engineered TIL cell therapies, supported by a $350 million private placement.

Galera Therapeutics reported the conversion of a significant portion of its Series B Preferred Stock into common stock and the exercise of pre-funded warrants by Ikarian Capital affiliates.

Galera Therapeutics has announced its 2025 and 2026 Annual Meeting of Stockholders will be held on May 8, 2026, with specific deadlines for stockholder proposals and director nominations.

Galera Therapeutics, Inc. has entered into a retention bonus agreement with its Chief Accounting Officer, Joel Sussman, for up to $250,000.

Galera Therapeutics, Inc. has completed the sale of its dismutase mimetic assets, including avasopasem and rucosopasem, to Biossil Inc., transferring associated liabilities.

Galera Therapeutics has entered into an agreement to sell its avasopasem and rucosopasem assets to Biossil Inc. for an upfront payment of $3.5 million and up to $105 million in potential future milestones.

Galera Therapeutics has amended its royalty agreement with Blackstone Life Sciences, reducing the royalty rate on avasopasem and rucosopasem to 4% following the suspension of product development.

Galera Therapeutics amends its Registration Rights Agreement, extending the deadline to file a registration statement to June 30, 2025.

Galera Therapeutics amends its previous 8-K filing regarding the acquisition of Nova Pharmaceuticals, citing SEC relief from certain financial reporting requirements.

Galera Therapeutics held its 2024 annual meeting of stockholders on February 24, 2025, where directors were elected and the appointment of KPMG LLP as the independent registered public accounting firm was ratified.

Galera Therapeutics has acquired Nova Pharmaceuticals, pivoting its development strategy towards anti-cancer therapeutics, particularly in resistant forms of breast cancer, and secured a concurrent financing to extend its cash runway into 2026.

Galera Therapeutics has scheduled its 2024 Annual Meeting for February 24, 2025, and established deadlines for stockholder proposals and director nominations.

Galera Therapeutics' stockholders voted against the proposed liquidation and dissolution of the company at a special meeting on October 17, 2024.

Galera Therapeutics will be delisted from the Nasdaq Stock Market after failing to meet minimum listing requirements, with trading continuing on the OTC Pink Market.

Galera Therapeutics has approved a plan to dissolve the company and liquidate its assets after failing to find suitable strategic alternatives, with a special stockholder meeting planned for October 17, 2024.

Galera Therapeutics has settled a lawsuit with its contract research organizations (CROs) related to a statistical error in a Phase 3 trial, receiving $975,000 and terminating contracts.

Galera Therapeutics has eliminated the Chief Operating Officer position as part of a strategic review and cost-saving initiative.

Galera Therapeutics has received notice from Nasdaq that its shares will be delisted due to failure to meet minimum listing requirements.

Galera Therapeutics reported a reduced net loss for Q1 2024 and is actively exploring strategic alternatives, including a potential sale or dissolution of the company.

Galera Therapeutics has adopted a stockholder rights agreement to protect shareholder value and prevent hostile takeovers.

Galera Therapeutics reported its 2023 financial results, highlighted by cost-cutting measures and a strategic review following regulatory setbacks for its lead drug candidate.

Galera Therapeutics has received notices from Nasdaq for failing to meet minimum market value and share price requirements, potentially leading to delisting.